Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Multiple Sclerosis

  Free Subscription


03.06.2019

1 Ann Neurol
2 Arch Phys Med Rehabil
1 Clin Ther
1 J Immunol
1 J Neuroimmunol
4 J Neurol
1 J Neurol Neurosurg Psychiatry
1 Lancet Neurol
7 Mult Scler
1 Nat Rev Neurol
2 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Neurol

  1. VAN LANGELAAR J, Rijvers L, Janssen M, Wierenga-Wolf AF, et al
    Induction of brain-infiltrating T-bet-expressing B cells in multiple sclerosis.
    Ann Neurol. 2019 May 28. doi: 10.1002/ana.25508.
    PubMed     Text format     Abstract available


    Arch Phys Med Rehabil

  2. CATTANEO D, Gervasoni E, Montesano A, Jonsdottir J, et al
    Response to Letter Regarding "Minimal Clinically Important Difference of Berg Balance Scale in People With Multiple Sclerosis".
    Arch Phys Med Rehabil. 2019;100:1191-1192.
    PubMed     Text format    

  3. OVACIK U, Celik D
    Minimal Clinically Important Difference of Berg Balance Scale in People With Multiple Sclerosis.
    Arch Phys Med Rehabil. 2019;100:1191.
    PubMed     Text format    


    Clin Ther

  4. REN J, Ascencio M, Raimondi T, Rainville EC, et al
    Association Between Exposure of Ipratropium and Salmeterol and Diagnosis of Multiple Sclerosis: A Matched Case-control Study.
    Clin Ther. 2019 May 22. pii: S0149-2918(19)30242.
    PubMed     Text format     Abstract available


    J Immunol

  5. PIANCONE F, Saresella M, Marventano I, La Rosa F, et al
    A Deficit of CEACAM-1-Expressing T Lymphocytes Supports Inflammation in Primary Progressive Multiple Sclerosis.
    J Immunol. 2019 May 29. pii: jimmunol.1801625. doi: 10.4049/jimmunol.1801625.
    PubMed     Text format     Abstract available


    J Neuroimmunol

  6. RASOOLI TEHRANI A, Gholipour S, Sharifi R, Yadegari S, et al
    Plasma levels of CTRP-3, CTRP-9 and apelin in women with multiple sclerosis.
    J Neuroimmunol. 2019;333:576968.
    PubMed     Text format     Abstract available


    J Neurol

  7. CHALMER TA, Kalincik T, Laursen B, Sorensen PS, et al
    Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy.
    J Neurol. 2019;266:306-315.
    PubMed     Text format     Abstract available

  8. D'AMICO E, Zanghi A, Sciandra M, Borriello G, et al
    Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience.
    J Neurol. 2019;266:411-416.
    PubMed     Text format     Abstract available

  9. GAETANI L, Salvadori N, Lisetti V, Eusebi P, et al
    Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis.
    J Neurol. 2019 May 25. pii: 10.1007/s00415-019-09398.
    PubMed     Text format     Abstract available

  10. LI H, Hu F, Zhang Y, Li K, et al
    Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
    J Neurol. 2019 May 25. pii: 10.1007/s00415-019-09395.
    PubMed     Text format     Abstract available


    J Neurol Neurosurg Psychiatry

  11. MARTIN SJ, McGlasson S, Hunt D, Overell J, et al
    Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case-control studies.
    J Neurol Neurosurg Psychiatry. 2019 May 23. pii: jnnp-2018-319190.
    PubMed     Text format     Abstract available


    Lancet Neurol

  12. JOKUBAITIS VG, Probstel AK, Arrambide G, Costello F, et al
    Introducing the International Women in Multiple Sclerosis network.
    Lancet Neurol. 2019;18:521.
    PubMed     Text format    


    Mult Scler

  13. CAPONE F, Collorone S, Cortese R, Di Lazzaro V, et al
    Fatigue in multiple sclerosis: The role of thalamus.
    Mult Scler. 2019 May 29:1352458519851247. doi: 10.1177/1352458519851247.
    PubMed     Text format     Abstract available

  14. MOBERG JY, Laursen B, Thygesen LC, Magyari M, et al
    Reproductive history of the Danish multiple sclerosis population: A register-based study.
    Mult Scler. 2019 May 30:1352458519851245. doi: 10.1177/1352458519851245.
    PubMed     Text format     Abstract available

  15. ARROYO R, Bury DP, Guo JD, Margolin DH, et al
    Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis.
    Mult Scler. 2019 May 30:1352458519849796. doi: 10.1177/1352458519849796.
    PubMed     Text format     Abstract available

  16. PELLEGRINI F, Copetti M, Bovis F, Cheng D, et al
    A proof-of-concept application of a novel scoring approach for personalized medicine in multiple sclerosis.
    Mult Scler. 2019 May 30:1352458519849513. doi: 10.1177/1352458519849513.
    PubMed     Text format     Abstract available

  17. AKGUN K, Ziemssen T
    Response to Hyun J.W. et al. "Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis".
    Mult Scler. 2019 May 30:1352458519854263. doi: 10.1177/1352458519854263.
    PubMed     Text format    

  18. MARRIE RA
    Recognizing the diversity gap in multiple sclerosis.
    Mult Scler. 2019 May 28:1352458519850070. doi: 10.1177/1352458519850070.
    PubMed     Text format    

  19. MCCOMBE PA
    Women who contributed to past research in multiple sclerosis.
    Mult Scler. 2019 May 28:1352458519846101. doi: 10.1177/1352458519846101.
    PubMed     Text format     Abstract available


    Nat Rev Neurol

  20. KELSEY R
    Phase II trial of evobrutinib in multiple sclerosis.
    Nat Rev Neurol. 2019 May 24. pii: 10.1038/s41582-019-0212.
    PubMed     Text format    


    PLoS One

  21. BEDRI SK, Nilsson OB, Fink K, Manberg A, et al
    Plasma protein profiling reveals candidate biomarkers for multiple sclerosis treatment.
    PLoS One. 2019;14:e0217208.
    PubMed     Text format     Abstract available

  22. EVDOSHENKO E, Stepanova A, Shumilina M, Davydovskaya M, et al
    Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia.
    PLoS One. 2019;14:e0217303.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: